Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
|
Ampio Pharmaceuticals, Inc. (AMPE)
|
Add to portfolio |
|
|
|
| Price: |
$1.69
| | Metrics |
| OS: |
15.1
|
M
| |
-213
|
% ROE
|
| Market cap: |
$25.5
|
M
| |
-11819
|
% ROIC
|
|
Net cash:
|
$6.95
|
M
| |
$0.46
|
per share
|
|
EV:
|
$18.6
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($5.1)
|
M
| |
|
|
|
EBIT
|
($5.8)
|
M
| |
|
|
| EPS |
($0.93)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -36.2 | -0.9 | 0.0 |
| Revenue growth | | | | | -100.0% | 3857.7% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -34.2 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -36.2 | 33.2 | 0.0 |
| Gross margin | | | | | | 100.0% | -3633.3% | |
| Selling, general and administrative | | | | | | | | |
| Research and development | 8.9 | 11.9 | 9.2 | 12.6 | 6.8 | 10.1 | 10.4 | 15.0 |
| General and administrative | 11.5 | 8.7 | 6.7 | 6.0 | 4.4 | 5.3 | 6.5 | 9.1 |
| EBIT | -9.1 | -17.1 | -16.5 | -13.8 | 34.0 | -51.9 | -19.2 | -33.7 |
| EBIT margin | | | | | | 143.3% | 2096.6% | |
| Pre-tax income | -16.3 | -17.1 | -15.9 | -13.6 | 34.0 | -51.9 | -19.2 | -33.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Earnings from continuing ops | -16.3 | -17.1 | -15.9 | -13.6 | 34.0 | -51.9 | -19.2 | -22.4 |
| Earnings from discontinued ops | | | | | | | | -9.6 |
| Net income | -16.3 | -17.1 | -15.9 | -13.6 | 34.0 | -51.9 | -19.2 | -32.0 |
| Net margin | | | | | | 143.3% | 2094.1% | |
| |
| Diluted EPS | ($1.08) | ($1.25) | ($0.09) | ($0.10) | $0.37 | ($0.79) | ($0.36) | ($0.43) |
| Shares outstanding (diluted) | 15.1 | 13.7 | 172.8 | 131.1 | 91.1 | 65.3 | 53.8 | 52.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|